Hong Kong Stocks Midday Update: Hang Seng Rises 0.28%; Biotech Index Extends Gains

Deep News07-16

Hong Kong's benchmark Hang Seng Index climbed 0.28% during the morning session, adding 68 points to reach 24,658. The Hang Seng Tech Index advanced 0.61% as morning turnover totaled HK$157.9 billion.

The biotech sector continued its upward trajectory following China's National Healthcare Security Administration announcement of a new commercial insurance catalog for innovative drugs, providing support for high-clinical-value medicines facing payment challenges. The Hang Seng Biotech Index rose with component stocks showing strong performance: Livzon Pharmaceutical Group (01513) surged 12.69%, Luye Pharma Group (02186) gained 7.69%, Fosun Pharma (02196) rose over 6%, and Akeso Inc. (09926) increased 6.88%.

Kuaishou-W (01024) climbed 1.76% to a two-year high amid UBS optimism about potential advertising acceleration in Q2 and valuation upside for its Kling business. Travel platforms advanced despite OTA competition concerns, with Tongcheng Travel (00780) up 3.32% and Trip.com Group-S (09961) rising 2.57%.

ANTA Sports (02020) added 2.73% after reporting mid-single-digit retail growth for its namesake brand in H1. Livzon Pharmaceutical (01513) jumped 12.69% upon completing patient enrollment for Phase II trials of its cardiovascular innovative drug H001 capsule. Innoscience (02577) climbed another 6.41% as the company plans significant expansion of 8-inch GaN wafer capacity over five years.

China XLX Fertiliser (01866) gained 3.83% after reports of government meetings on potash supply stabilization, with analysts predicting sustained industry momentum. Chongqing Machinery (02722) soared over 17% as domestic AIDC developments progressed, with its Cummins venture serving as engine supplier. Jufang Investment Holdings (09636) surged 10.18% after proposing a share placement to raise approximately HK$746 million for developing chain financial resources.

On the downside, SMOORE International (06969) fell 3.55% after projecting H1 profit decline of 21%-35%. Pharmaron Beijing (03759) dropped 5.24% following a profit warning indicating expected 36%-39% decrease in H1 net profit attributable to owners.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment